SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-050290
Filing Date
2021-09-28
Accepted
2021-09-28 16:02:14
Documents
70
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea147969-6k_nlspharma.htm   iXBRL 6-K 17763
2 CONDENSED FINANCIAL STATEMENTS (UNAUDITED) OF NLS PHARMACEUTICS AS OF AND FOR TH ea147969ex99-1_nlspharma.htm   iXBRL EX-99.1 320459
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea147969ex99-2_nlspharma.htm EX-99.2 142323
  Complete submission text file 0001213900-21-050290.txt   3117379

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20210630.xsd EX-101.SCH 50481
5 XBRL CALCULATION FILE nlsp-20210630_cal.xml EX-101.CAL 30650
6 XBRL DEFINITION FILE nlsp-20210630_def.xml EX-101.DEF 166465
7 XBRL LABEL FILE nlsp-20210630_lab.xml EX-101.LAB 336180
8 XBRL PRESENTATION FILE nlsp-20210630_pre.xml EX-101.PRE 177025
9 EXTRACTED XBRL INSTANCE DOCUMENT ea147969-6k_nlspharma_htm.xml XML 237264
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 211286729
SIC: 2834 Pharmaceutical Preparations